ReviewJournal of industrial microbiology & biotechnology2017
An overview of rapamycin: from discovery to future perspectives.
Review in Journal of industrial microbiology & biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 109 citations in OpenAlex.
- Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.Movement disorders clinical practice · 2026Review
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy.Journal of molecular modeling · 2026Article
- Systematic Profiling of Essential Fungal Transcription Factors Uncovers Ezt1 as a Central Pathobiological and Morphogenic Regulator inResearch square · 2026Article
- Systematic Profiling of Essential Fungal Transcription Factors Uncovers Ezt1 as a Central Pathobiological and Morphogenic Regulator inbioRxiv : the preprint server for biology · 2026Article
- Developing the protein quality control system inSynthetic and systems biotechnology · 2026Article
- Sirolimus application in patients with autoimmune-associated kidney diseases based on mTORC1 activation: a preliminary exploration and future perspectives.Frontiers in pharmacology · 2026Article
- Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Frontiers in immunology · 2026Review
- Exosomal immune decoy integrates cfDNA scavenging and mTOR inhibition for synergistic lupus nephritis therapy.Theranostics · 2026Article
- Role of autophagy in rejection after solid organ transplantation: A systematic review of the literature.World journal of transplantation · 2025Review
- Rapamycin Plays a Pivotal Role in the Potent Antifungal Activity Exhibited AgainstMicroorganisms · 2025Article
- Insights into the roles of exogenous phenylalanine and tyrosine in improving rapamycin production of Streptomyces rapamycinicus with transcriptome analysis.Microbial cell factories · 2024Article
- The Effect of Chronic Immunosuppressive Regimen Treatment on Apoptosis in the Heart of Rats.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Structure of prolylrapamycin: confirmation through a revised and detailed NMR assignment study.The Journal of antibiotics · 2024Article
- Natural Products That Contain Higher Homologated Amino Acids.Chembiochem : a European journal of chemical biology · 2024Review
- The shikimate pathway: gateway to metabolic diversity.Natural product reports · 2024Review
- A Low Dose of Rapamycin Promotes Hair Cell Differentiation by Enriching SOX2Journal of the Association for Research in Otolaryngology : JARO · 2024Article
- Review
- Discovery of thiazostatin D/E using UPLC-HR-MS2-based metabolomics and σ-factor engineering ofFrontiers in bioengineering and biotechnology · 2024Article
- TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth.Cancers · 2023Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapamycin is an immunosuppressive metabolite produced from several actinomycete species. Besides its immunosuppressive activity, rapamycin and its analogs have additional therapeutic potentials, including antifungal, antitumor, neuroprotective/neuroregenerative, and lifespan extension activities. The core structure of rapamycin is derived from (4R,5R)-4,5-dihydrocyclohex-1-ene-carboxylic acid that is extended by polyketide synthase. The resulting linear polyketide chain is cyclized by incorporating pipecolate and further decorated by post-PKS modification enzymes. Herein, we review the discovery and biological activities of rapamycin as well as its mechanism of action, mechanistic target, biosynthesis, and regulation. In addition, we introduce the many efforts directed at enhancing the production of rapamycin and generating diverse analogs and also explore future perspectives in rapamycin research. This review will also emphasize the remarkable pilot studies on the biosynthesis and production improvement of rapamycin by Dr. Demain, one of the world's distinguished scientists in industrial microbiology and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.